Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HICARi study of ASP-1929 photoimmunotherapy for EGFR-positive recurrent or persistent gynecologic vulvar/vaginal/cervical lesions
jRCT2011240034Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab sarotalocan sodium in Vulval carcinoma, vaginal cancer and Cervical Cancer (CC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Tumor shrinkage effect in laser-illuminated lesions. Started Oct 2024; status: recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
Vulval carcinomavaginal cancerCervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2011240034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240034.